Sanofi SA (SNY) Position Reduced by Global Financial Private Capital LLC
Global Financial Private Capital LLC lowered its position in Sanofi SA (NYSE:SNY) by 32.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 330,117 shares of the company’s stock after selling 158,975 shares during the period. Global Financial Private Capital LLC’s holdings in Sanofi were worth $14,195,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Bank of Nova Scotia Trust Co. acquired a new stake in Sanofi in the third quarter valued at about $125,000. Bronfman E.L. Rothschild L.P. lifted its position in Sanofi by 46.0% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock valued at $186,000 after purchasing an additional 1,362 shares during the period. Toronto Dominion Bank lifted its position in Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after purchasing an additional 180 shares during the period. SeaCrest Wealth Management LLC acquired a new stake in Sanofi in the fourth quarter valued at about $200,000. Finally, Mraz Amerine & Associates Inc. acquired a new stake in Sanofi in the third quarter valued at about $204,000. Hedge funds and other institutional investors own 9.07% of the company’s stock.
Sanofi SA (NYSE:SNY) opened at $39.40 on Wednesday. Sanofi SA has a 1-year low of $38.14 and a 1-year high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The stock has a market cap of $99,826.51, a PE ratio of 12.69, a price-to-earnings-growth ratio of 2.07 and a beta of 0.85.
The business also recently announced an annual dividend, which will be paid on Monday, June 4th. Shareholders of record on Thursday, May 10th will be issued a $1.8609 dividend. The ex-dividend date is Wednesday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.58. This represents a yield of 4.72%. Sanofi’s dividend payout ratio (DPR) is 30.14%.
SNY has been the subject of a number of recent analyst reports. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 6th. Morgan Stanley downgraded shares of Sanofi from an “overweight” rating to an “underweight” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Thursday, December 14th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Finally, Nord/LB restated a “neutral” rating on shares of Sanofi in a research report on Wednesday, December 27th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. Sanofi has an average rating of “Hold” and a consensus target price of $49.33.
COPYRIGHT VIOLATION WARNING: “Sanofi SA (SNY) Position Reduced by Global Financial Private Capital LLC” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2018/02/14/sanofi-sa-sny-position-reduced-by-global-financial-private-capital-llc.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.